IGM Biosciences (IGMS) Stock Price, News & Analysis

Company Overview

IGM Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel immunotherapies based on engineered immunoglobulin M (IgM) antibodies. Utilizing a proprietary IgM platform, the company aims to harness the high avidity and potent complement activation properties of pentameric IgM molecules to address a range of oncology and infectious disease targets. By leveraging this unique antibody format, IGM Biosciences seeks to overcome limitations of conventional IgG therapeutics and deliver improved binding strength and efficacy.

The company’s lead oncology candidates include IGM‐2323, an anti‐CD20 IgM antibody in Phase 1/2 development for relapsed or refractory non‐Hodgkin lymphoma, and IGM‐8444, an anti‐death receptor 5 (DR5) IgM molecule targeting solid tumors. Both programs are designed to induce tumor cell lysis through enhanced complement-dependent cytotoxicity and immune effector engagement. In addition to its oncology pipeline, IGM Biosciences is advancing early‐stage programs in infectious diseases and autoimmunity, illustrating the versatility of its IgM platform across multiple therapeutic areas.

Founded in 2014 and headquartered in Carlsbad, California, IGM Biosciences went public on the NASDAQ in June 2020. The company conducts its research, development, and early clinical studies primarily in the United States, while collaborating with academic and industry partners to support global trial initiatives. IGM Biosciences maintains research facilities in California and has established strategic alliances to expand its scientific capabilities and accelerate its pipeline.

Under the leadership of President and Chief Executive Officer Andrew Adams, IGM Biosciences has grown its multidisciplinary team of antibody engineers, clinical development experts, and regulatory specialists. The company continues to advance its novel IgM therapeutics with the goal of delivering first‐in‐class treatments for patients with high unmet medical needs in oncology and beyond.

Key Stats

• Today's Range: $1.27 to $1.27
• 50-Day Range: $1.26 to $1.36
• 52-Week Range: $0.92 to $22.50
• Volume: N/A
• Average Volume: 480,746 shs
• Market Capitalization: $76.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.89
• Consensus Rating: Reduce

IGM Biosciences Stock Analysis - MarketRank™

IGM Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 206th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

IGM Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.

Upside Potential

IGM Biosciences has a consensus price target of $4.89, representing about 285.0% upside from its current price of $1.27.

Amount of Analyst Coverage

IGM Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IGM Biosciences are expected to grow in the coming year, from ($3.35) to ($0.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IGM Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IGM Biosciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IGM Biosciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IGMS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IGM Biosciences does not currently pay a dividend.

Dividend Growth

IGM Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -1.08

Short Interest

There is no current short interest data available for IGMS.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for IGMS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

3 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,494.00 in company stock.

Percentage Held by Insiders

57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IGMS Stock Analysis - Frequently Asked Questions

How have IGMS shares performed this year?

IGM Biosciences' stock was trading at $6.11 at the beginning of the year. Since then, IGMS stock has decreased by 79.2% and is now trading at $1.27.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) released its quarterly earnings data on Thursday, July, 31st. The company reported $1.58 EPS for the quarter, topping the consensus estimate of ($0.30) by $1.88. The firm earned $143.62 million during the quarter, compared to analysts' expectations of $3.20 million. IGM Biosciences had a negative trailing twelve-month return on equity of 93.35% and a negative net margin of 36.81%.

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering on Wednesday, September 18th 2019. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are IGM Biosciences' major shareholders?

IGM Biosciences' top institutional shareholders include Geode Capital Management LLC (0.35%), Jane Street Group LLC (0.30%), Marshall Wace LLP (0.07%) and XTX Topco Ltd (0.04%). Insiders that own company stock include Bros Advisors Lp Baker, Mary Beth Harler, Fred Schwarzer, Misbah Tahir, Bruce Keyt, Jakob Haldor Topsoe, Lisa Lynn Decker, Chris H Takimoto, George Gauthier, Michael D Loberg, Steven Weber and Julie Hambleton.
View institutional ownership trends.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IGMS
• CIK: 1496323
• Web: igmbio.com
• Phone: 650-965-7873
• Fax: N/A
• Employees: 190
• Year Founded: 2010

Price Target and Rating

• Average Price Target for IGM Biosciences: $4.89
• High Price Target: $20.00
• Low Price Target: $1.50
• Potential Upside/Downside: +285.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$195.79 million
• Net Margins: -36.81%
• Pretax Margin: -36.81%
• Return on Equity: -93.35%
• Return on Assets: -24.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.66
• Quick Ratio: 17.66

Sales & Book Value

• Annual Sales: $145.05 million
• Price / Sales: 0.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 60,293,000
• Free Float: 25,926,000
• Market Cap: $76.57 million
• Optionable: Optionable
• Beta: 0.60